2022
New Onset Isolated Granulomatous Dacryoadenitis During Etanercept Therapy
Arat Y, Aygün F, Özoğul E, Kalyoncu U. New Onset Isolated Granulomatous Dacryoadenitis During Etanercept Therapy. Ocular Immunology And Inflammation 2022, 31: 1727-1729. PMID: 35797360, DOI: 10.1080/09273948.2022.2089687.Peer-Reviewed Original ResearchMeSH KeywordsAdultDacryocystitisEtanerceptFemaleGranulomaHumansLacrimal ApparatusSarcoidosisYoung AdultConceptsEtanercept therapyLacrimal glandLeft upper eyelid swellingAnti-tumor necrosis factor alphaUpper eyelid swellingLeft lacrimal glandRight lacrimal glandSarcoid-like granulomatosisNecrosis factor-alphaJuvenile idiopathic arthritisAntagonist therapyEyelid swellingIncisional biopsySubcutaneous etanerceptDiffuse enlargementFactor-alphaTNF-aDacryoadenitisIdiopathic arthritisMinimal enlargementTherapyBiological agentsEtanerceptGlandEnlargement
2019
Retinal and Choroidal Optical Coherence Tomography Findings of Carotid Cavernous Fistula
Inam O, Arat Y, Yavas G, Arat A. Retinal and Choroidal Optical Coherence Tomography Findings of Carotid Cavernous Fistula. American Journal Of Ophthalmology 2019, 206: 264-273. PMID: 31226247, DOI: 10.1016/j.ajo.2019.06.010.Peer-Reviewed Original ResearchConceptsChoroidal vascularity indexTortuosity indexPatient groupControl groupCentral foveal thicknessClinically affected eyesSubfoveal choroidal thicknessOptical coherence tomography imagesVenous drainage patternCarotid-cavernous fistulaHealthy control subjectsCG groupFoveal thicknessChoroidal thicknessCavernous fistulaConsecutive patientsControl subjectsVascular indexPatientsTomography imagesFistulaSFCTEyesGroupClinic
2015
Association of Disease Activity with Serum and Tear IL-2 Levels in Behçet Disease
Türkçüoğlu P, Arat Y, Kan E, Kan E, Chaudhry I, Koca S, Çeliker Ü, İlhan N. Association of Disease Activity with Serum and Tear IL-2 Levels in Behçet Disease. Ocular Immunology And Inflammation 2015, 24: 313-318. PMID: 26110544, DOI: 10.3109/09273948.2014.1003661.Peer-Reviewed Original ResearchConceptsIL-2 levelsInterleukin-2 levelsDisease activitySex-matched healthy participantsProspective case control studyAssociation of disease activitySignificant differenceBehcet's disease patientsCase-control studyStatistically significant differenceEnzyme-linked immunosorbent assay methodBehcet's patientsBehcet's diseaseActive diseaseInactive diseaseNo significant differenceControlled studiesPatientsStudy populationSerumDisease patientsControl groupDiseaseHealthy participantsAssociation
2011
Orbitofacial neurofibromatosis: clinical characteristics and treatment outcome
Chaudhry I, Morales J, Shamsi F, Al-Rashed W, Elzaridi E, Arat Y, Jacquemin C, Oystreck D, Bosley T. Orbitofacial neurofibromatosis: clinical characteristics and treatment outcome. Eye 2011, 26: 583-592. PMID: 22193879, PMCID: PMC3325560, DOI: 10.1038/eye.2011.336.Peer-Reviewed Original ResearchConceptsSurgical interventionNon-comparative case seriesDecreased visual acuityNeurofibromatosis type 1Ophthalmologic examinationOphthalmological monitoringPtosis repairTumor debulkingEyelid swellingVisual acuityResultsSixty patientsSurgical managementCase seriesPresenting signCosmetic consequencesCosmetic rehabilitationProcedural outcomesPatientsMedical recordsType 1Medical CentreMultiple proceduresClinical observationsDemographic dataPtosis